Healthcare · Profile from Healthcare Research Companion
Medtronic plc
The world's largest pure-play medical device company by revenue. It began in 1949 as a Minneapolis garage business repairing hospital equipment, became the pioneer of battery-powered and implantable pacemakers, and grew through acquisitions into a ~$36bn-a-year maker of cardiac, surgical, neuroscience and diabetes devices. Its defining strategic moves are the 2015 Covidien merger, structured as a tax inversion to Ireland; the 2001 MiniMed purchase that put it in diabetes, and the 2025–26 separation of that business as MiniMed; and a long record of recalls and controversies (Sprint Fidelis leads, Infuse bone graft, the HeartWare HVAD pump, insulin pump warning letters) that shows how device risk is managed and mismanaged.
At a glance
- Founded
- 29 April 1949, Minneapolis, Minnesota, as a medical equipment repair shop
- Founders
- Earl Bakken (electrical engineering graduate student) and Palmer Hermundslie (his brother-in-law)
- Headquarters
- Legal domicile and principal executive office in Dublin, Ireland, since 2015; operational headquarters in Fridley (Minneapolis), Minnesota
- Ownership / structure
- Public company, NYSE: MDT; fiscal year ends on the last Friday of April
- Leadership (2026)
- Geoff Martha, chairman and CEO (CEO since April 2020); Thierry Piéton, CFO (verify); board refreshed in 2025 after Elliott Management took a stake (reported)
- Segment and buyer
- Cardiovascular (pacemakers, defibrillators, ablation, TAVR, renal denervation), Medical Surgical (staplers, energy, robotics, monitoring), Neuroscience (spine, neuromodulation, cranial, ENT), Diabetes (pumps and CGMs, being separated as MiniMed); buyers are hospitals, ambulatory surgery centres and, for diabetes, patients via DME suppliers and pharmacies; payers Medicare, commercial plans and national systems
- Scale
- FY2026 (year to April 2026) revenue ~$36.4bn (+8.4% reported, +5.8% organic); non-GAAP operating margin ~24.4% (reported); ~95,000 employees (verify); products used on a patient every ~1–2 seconds (company claim)
- Capital / market cap
- Investment-grade debt; ~$49.9bn Covidien deal paid in cash and Medtronic shares, the cash portion funded by ~$17bn of bonds (December 2014), which replaced ~$16bn of committed bridge financing (reported); market cap roughly $110–130bn in 2025–26 (verify)
- Signature moves (incl. failures)
- Wearable battery pacemaker (1957); implantable pacemaker licence (1960); MiniMed (2001); Sprint Fidelis lead recall (2007); Infuse bone graft controversy (2011–12); Covidien inversion (2015); MiniMed 670G hybrid closed loop (2016) and FDA warning letter (2021); HeartWare (2016) and HVAD withdrawal (2021); patient-care products sold to Cardinal (2017); Affera and pulsed field ablation (2022–24); diabetes separation and MiniMed IPO (2025–26)
8 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
1957
Wearable Pacemaker and Founding
Founding (1949) / launch (1957 wearable pacemaker; 1960 implantable pacemaker licence)
2001
MiniMed Acquisition
Acquisition
2011
Infuse Bone Graft Controversy
Evidence scandal / regulatory and legal exposure
2015
Covidien Inversion
Merger / tax inversion
2016
MiniMed 670G and Warning Letter
Launch / regulatory enforcement
2021
HVAD Discontinuation
Recall / product withdrawal / write-down
2022
Affera Pulsed Field Ablation
Acquisition / launch
2025
Diabetes Separation MiniMed IPO
Spin-off / IPO (two-step separation)